Search results for "Colony-Stimulating Factor"

showing 10 items of 174 documents

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myel…

2007

Abstract The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-donor comparison. Between 1987 and 2004, 2287 pts were entered in these studies of whom 1032 pts (45%) without FAB M3 or t(15;17) were in CR1 after 2 cycles of chemotherapy, received consolidation treatment, and were younger than 55 years of age and therefore eligible for allogeneic hematopoietic stem cell transplantation (allo-SCT). An HLA-identical sibling donor was available for 326 pt…

MaleMyeloidTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationBiochemistryGastroenterologyRecurrenceRisk FactorsUNRELATED DONORSLiving DonorsMedicineTOTAL-BODYACUTE MYELOGENOUS LEUKEMIAHistocompatibility TestingAge FactorsHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyCOLONY-STIMULATING FACTORMiddle AgedChemotherapy regimenSurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureFemalePOSTREMISSION THERAPYAdultmedicine.medical_specialtyAcute myeloblastic leukemiaAdolescentImmunologymacromolecular substancesDisease-Free SurvivalMeta-Analysis as TopicInternal medicineotorhinolaryngologic diseasesHumansTransplantation HomologousSurvival rateRetrospective StudiesEUROPEAN GROUPbusiness.industryACUTE MYELOBLASTIC-LEUKEMIACell Biologymedicine.diseaseBONE-MARROW-TRANSPLANTATIONINTENSIVE CHEMOTHERAPYSurgeryTransplantationAML-10 TRIALbusinessFollow-Up StudiesBlood
researchProduct

Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes.

1997

Bone marrow (BM) failure associated with cytomegalovirus (CMV) infection is a feared complication after clinical BM transplantation. Experiments in long-term BM cultures have indicated that BM stromal cells (BMSC) are targets of productive CMV infection, but an in situ infection of BM stroma remained to be documented, and the pathomechanism is open to question. Here we describe a murine in vivo model of lethal CMV aplastic anemia (CMV-AA). The reconstitution of hematopoietic progenitor cells expressing stem cell factor (SCF) receptor was found to be defective in CMV-AA. While murine CMV replication in permissive parenchymal tissues is cytolytic, the hematopoietic cord was found to be a site…

MaleStromal cellImmunologyGene ExpressionStem cell factorBiologyHematopoietic Cell Growth FactorsMicrobiologyMiceBone MarrowVirologyGranulocyte Colony-Stimulating FactormedicineAnimalsRNA MessengerAplastic anemiaMice Inbred BALB CStem Cell FactorInterleukin-6Hematopoietic Cell Growth FactorsBone marrow failureAnemia Aplasticmedicine.diseaseHematopoiesisTransplantationHaematopoiesisProto-Oncogene Proteins c-kitmedicine.anatomical_structureInsect ScienceImmunologyCytomegalovirus InfectionsFemaleBone marrowResearch Article
researchProduct

Cancer in the older person.

2005

Cancer in the older person is an increasingly common problem, due to the progressive prolongation of the life-expectancy of the Western population. This article reviews the mechanisms associating aging and cancer, age-related changes in cancer biology, assessment of the older person to estimate life-expectancy, treatment tolerance, and medical and social conditions that may interfere with cancer treatment, effectiveness of cancer prevention and cancer treatment in older individuals. A comprehensive geriatric assessment (CGA) is commonly used to predict life-expectancy and functional reserve and to unearth conditions that may jeopardize cancer prevention and treatment. In the interest of cos…

Malemedicine.medical_specialtyColorectal cancerPopulationPRIMARY-CARE PATIENTSPainDiseaseProstate cancerNeoplasmsMedicineHumansPain ManagementRadiology Nuclear Medicine and imagingNON-HODGKINS-LYMPHOMAIntensive care medicineeducationELDERLY-PATIENTSGeriatric AssessmentSURGICAL ADJUVANT BREASTPreventive healthcareAgededucation.field_of_studyCancer preventionbusiness.industryCOMPREHENSIVE GERIATRIC ASSESSMENTCancerGeneral MedicineRANDOMIZED CONTROLLED-TRIALCOLONY-STIMULATING FACTORmedicine.diseasePROSTATE-CANCERClinical trialOncologyCOOPERATIVE-ONCOLOGY-GROUPPhysical therapyDIFFUSE HISTIOCYTIC LYMPHOMAFemalebusinessCancer treatment reviews
researchProduct

Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors—A Breakthrough in the Treatment of Cancer Patients with Febrile Neutr…

2021

(1) Background: Febrile neutropenia (FN) remains one of the most challenging problems in medical oncology and is a very severe side effect of chemotherapy. Its late consequences, when it is recurrent or of a severe grade, are dose reduction and therapy delays. Current guidelines allow the administration of granulocyte-colony-stimulating factors (G-CSF) for profound FN (except for the case when a pegylated form of G-CSF is administrated with prophylactic intention) in addition to antibiotics and supportive care. (2) Methods: This is a prospective study that included 96 patients with confirmed malignancy, treated with chemotherapy, who developed FN during their oncological therapy, and were h…

Malemedicine.medical_specialtyMedicine (General)Side effectmedicine.medical_treatmentNeutropeniaG-CSFfebrilechemotherapyGastroenterologyArticleProcalcitoninR5-920NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansneutropeniacancerProspective StudiesProspective cohort studyFebrile NeutropeniaChemotherapybiologybusiness.industryStandard treatmentC-reactive proteinGeneral Medicinemedicine.diseasebiology.proteinAdministration IntravenousFemalebusinessFebrile neutropeniaGranulocytesMedicina
researchProduct

The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis.

2005

G-CSF is a potent hematopoietic factor that enhances survival and drives differentiation of myeloid lineage cells, resulting in the generation of neutrophilic granulocytes. Here, we show that G-CSF passes the intact blood-brain barrier and reduces infarct volume in 2 different rat models of acute stroke. G-CSF displays strong anti-apoptotic activity in mature neurons and activates multiple cell survival pathways. Both G-CSF and its receptor are widely expressed by neurons in the CNS, and their expression is induced by ischemia, which suggests an autocrine protective signaling mechanism. Surprisingly, the G-CSF receptor was also expressed by adult neural stem cells, and G-CSF induced neurona…

Malemedicine.medical_specialtyProgrammed cell deathNeutrophilsCellular differentiationApoptosisBiologyLigandsBrain IschemiaBrain ischemiaInternal medicineGranulocyte Colony-Stimulating FactormedicineAnimalsHumansGranulocyte Precursor CellsNerve TissueRats WistarReceptorAutocrine signallingStem CellsNeurogenesisCell DifferentiationNeurodegenerative DiseasesGeneral Medicinemedicine.diseaseNeural stem cellCell biologyRatsStrokeDisease Models AnimalEndocrinologyBlood-Brain BarrierReceptors Granulocyte Colony-Stimulating FactorStem cellResearch ArticleThe Journal of clinical investigation
researchProduct

Different postischemic protein expression of the GABA_{A} receptor α2 subunit and the plasticity-associated protein MAP1B after treatment with BDNF v…

2009

Purpose Recent data indicate that both brain-derived neurotrophic factor (BDNF) and granulocyte-colony stimulating factor (G-CSF) exert substantial neuroregenerative effects and improve functional outcome after ischemic stroke. In the present study, we checked for potential differences in the postischemic modulation of various excitatory and inhibitory neurotransmitter receptors as well as various marker molecules for structural plasticity by BDNF versus G-CSF. Methods Adult male Wistar rats were subjected to photothrombotic ischemia and subsequently treated with NaCl, BDNF or G-CSF, respectively. After 6 weeks, postischemic protein expression of the NR1, GluR1 and alpha2 subunit of the NMD…

Malemedicine.medical_specialtyProtein subunitSynaptophysinHippocampusAMPA receptorFunctional LateralityRandom AllocationDevelopmental NeuroscienceNeurotrophic factorsInternal medicineGranulocyte Colony-Stimulating FactormedicineAnimalsRats WistarReceptorAnalysis of VariancebiologyChemistryGABAA receptorBrain-Derived Neurotrophic FactorBrainReceptors GABA-ARatsStrokeDisease Models AnimalEndocrinologyGene Expression Regulationnervous systemNeurologySynaptophysinbiology.proteinNMDA receptorNeurology (clinical)Intracranial ThrombosisMicrotubule-Associated ProteinsRestorative Neurology and Neuroscience
researchProduct

Gamma-Interferon Regulates Secretion of G-CSF in Human Monocytes on the Transcriptional Level

1987

The production of colony stimulating factors (CSF) for granulocytes and monocytes is integrated into a network of communicating soluble messenger molecules resulting from T-cell/monocyte interactions. We assessed the capactiy of gamma-Interferon to modulate monocyte secretion of CSF by colony assays and Northern blot analysis to hybridize monocyte RNA with cDNA probes of different CSF-types. Whereas mRNA for GM-CSF was undetectable in untreated and gamma-IFN treated peripheral blood monocytes, the constitutive expression of mRNA for G-CSF and subsequent production of a CSF with biological activities similar to G-CSF could highly be enhanced by exposure of monocytes to gamma-IFN.

Messenger RNAmedicine.anatomical_structureChemistryComplementary DNAMonocyteGamma interferonmedicineRNASecretionNorthern blotColony-stimulating factorMolecular biology
researchProduct

Modulation of accessory cell function of immortalized bone marrow-derived macrophages by granulocyte/macrophage colony-stimulating factor.

1993

To generate cloned macrophage populations with sensitivity towards granulocyte/macrophage colony-stimulating factor (GM-CSF), bone marrow-derived macrophages (BMM phi) were immortalized by transformation with SV40. A panel of transformed clones was established. The majority of clones represented independently derived transformants, as evidenced by restriction fragment length polymorphism using genomic DNA digested with EcoRI and TaqI and the 5.2 kb SV40 DNA for hybridization analysis. The cells belong to the macrophage lineage according to several criteria, e.g. the presence of nonspecific esterase, their phagocytic capacity and their morphology. Many clones were potent antigen-presenting c…

Microbiology (medical)ImmunologyAntigen presentationAntigen-Presenting CellsBone Marrow CellsSimian virus 40BiologyGranulocyteMicePhagocytosismedicineImmunology and AllergyMacrophageAnimalsAntigen-presenting cellCells CulturedMice Inbred C3HMacrophage Colony-Stimulating FactorMacrophagesHistocompatibility Antigens Class IIGranulocyte-Macrophage Colony-Stimulating FactorGeneral MedicineBlotting NorthernCell Transformation ViralMolecular biologyClone CellsBlotmedicine.anatomical_structureGranulocyte macrophage colony-stimulating factorCell cultureImmunologyDNA ViralBone marrowDNA ProbesPolymorphism Restriction Fragment Lengthmedicine.drugMedical microbiology and immunology
researchProduct

Granulocyte–Colony Stimulating Factor plus Plerixafor in Patients with β-thalassemia Major Results in the Effective Mobilization of Primitive CD34+ C…

2017

Successful gene therapy for β-thalassemia requires optimal numbers of autologous gene-transduced hematopoietic stem and progenitor cells (HSPCs) with high repopulating capacity. Previous studies suggested superior mobilization in these patients by the combination of granulocyte–colony stimulating factor (G-CSF) plus plerixafor over single agents. We mobilized four adult patients using G-CSF+plerixafor to assess the intra-individual variation of the circulating CD34+ cells number and subtypes preand post-plerixafor administration. The procedure was well-tolerated and the target cell dose of ≥8×10 6 CD34+ cells/kg was achieved in three of them with one apheresis procedure. The addition of ple…

Mobilizationbusiness.industryCD34+ cells expression profilingCd34 cellsPlerixaforGenetic enhancementβ-thalassemia; CD34 cells expression profiling; G-CSF plerixafor mobilization; gene therapygene therapySettore MED/15 - Malattie Del SangueGranulocyte colony-stimulating factorSettore BIO/18 - Geneticagene therapy.β-thalassemiaGene expressionImmunologyCancer researchG-CSF+plerixafor mobilizationMedicineDiseases of the blood and blood-forming organsIn patientβ-thalassemia; CD34+ cells expression profiling; G-CSF+plerixafor mobilization; gene therapyRC633-647.5businessβ thalassemia majormedicine.drugThalassemia Reports
researchProduct

Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in au…

1989

Autonomous in vitro growth of myeloid leukemic colony-forming cells may in part result from autocrine production of colony-stimulating factors (CSF). Some acute myeloid leukemia (AML) samples, however, fail to synthesize CSF despite growing autonomously in agar, and are therefore believed to bypass CSF requirements. Cytokines such as IL-6, tumor necrosis factor (TNF)-alpha, and IL-1, products of cells of the myeloid lineage, are known to be involved in growth control of myeloid progenitor cells. Since these molecules may also contribute to autocrine and paracrine growth regulation of myeloid leukemias, we screened a series of AML for cytokine production. In addition, possible roles of IL-6,…

Myeloidmedicine.medical_treatmentMyeloid leukemiaGeneral MedicineBiologymedicine.diseaseColony-stimulating factorMyelogenousLeukemiaParacrine signallingmedicine.anatomical_structureCytokinehemic and lymphatic diseasesImmunologymedicineAutocrine signallingResearch Article
researchProduct